Regencell Bioscience Holdings Limited (RGC) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 6, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 20-F for FY2025, filed Oct 31, 2025. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the RGC SEC filings page.
This page shows Regencell Bioscience Holdings Limited (RGC) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Regencell Bioscience Holdings Limited does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Regencell Bioscience Holdings Limited passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Regencell Bioscience Holdings Limited reported a net loss of $3.6M while operations used $3.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
None of these metrics is reported for Q4 2025.
Cash & Balance Sheet
Regencell Bioscience Holdings Limited held $2.4M in cash as of Q4 2025; long-term debt is not reported for that period.
Not reported for Q4 2025.
Not reported for Q4 2025.
Margins & Returns
None of these metrics is reported for Q4 2025.
Capital Allocation
None of these metrics is reported for Q4 2025.
RGC Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, Interest Expense, Income Tax, Net Income, EPS (Basic), EPS (Diluted), Diluted Shares (Avg).
RGC Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2520-F | Q4'2420-F | Q4'2310-K | Q4'2210-K | Q4'2110-K | Q4'2010-K |
|---|---|---|---|---|---|---|
| Total Assets | $5.8M-31.8% | $8.4M-33.1% | $12.6M-30.0% | $18.0M+5197.6% | $340K-33.8% | $514K |
| Current Assets | $4.9M-39.6% | $8.1M-30.2% | $11.6M-29.3% | $16.4M+24499.6% | $67K-82.7% | $387K |
| Cash & Equivalents | $2.4M-18.3% | $3.0M+89.2% | $1.6M-75.6% | $6.4M+10700.7% | $59K-84.6% | $387K |
| Short-Term Investments | $2.5M-50.4% | $5.0M-50.0% | $10.0M0.0% | $10.0M | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $895K+307.9% | $220K-65.3% | $632K-32.6% | $938K-78.4% | $4.3M+37.1% | $3.2M |
| Current Liabilities | $664K+242.8% | $194K-68.1% | $607K+5.0% | $578K-86.7% | $4.3M+37.1% | $3.2M |
| Non-Current Liabilities | $232K+793.2% | $26K+2.1% | $25K-92.9% | $360K | $0 | $0 |
| Total Equity | $4.9M-40.9% | $8.2M-31.7% | $12.0M-29.5% | $17.1M+526.9% | -$4.0M-50.8% | -$2.7M |
| Retained Earnings | -$25.2M-16.6% | -$21.6M-24.8% | -$17.3M-51.3% | -$11.4M-186.2% | -$4.0M-50.8% | -$2.7M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
RGC Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Operating Cash Flow, Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.
RGC Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Return on Assets, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Regencell Bioscience Holdings Limited RGC | FY2025 | N/A | -$3.6M | N/A | $3.6B | — |
| Elanco Animal Health Incorporated ELAN | FY2025 | $4.7B | -$232.0M | -4.9% | $11.2B | 36/100 |
| Alkermes Inc. plc ALKS | FY2025 | $1.5B | $241.7M | 16.4% | $7.2B | 73/100 |
| Lantheus Holdings, Inc LNTH | FY2025 | $1.5B | $233.6M | 15.2% | $6.5B | 71/100 |
| Prestige Consumer Healthcare Inc. PBH | FY2026 | $1.1B | $190.3M | 17.5% | $2.2B | 61/100 |
| Amneal Pharmaceuticals, Inc. AMRX | FY2025 | $3.0B | $72.1M | 2.4% | $7.1B | 56/100 |
Where Regencell Bioscience Holdings Limited Ranks
Frequently Asked Questions
Is Regencell Bioscience Holdings Limited profitable?
No, Regencell Bioscience Holdings Limited (RGC) reported a net income of -$3.6M in fiscal year 2025.
What is Regencell Bioscience Holdings Limited's EBITDA?
Regencell Bioscience Holdings Limited (RGC) had EBITDA of -$3.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Regencell Bioscience Holdings Limited's return on equity (ROE)?
Regencell Bioscience Holdings Limited (RGC) has a return on equity of -73.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Regencell Bioscience Holdings Limited's free cash flow?
Regencell Bioscience Holdings Limited (RGC) recorded an outflow of $3.3M in free cash flow during fiscal year 2025. This represents a 18.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Regencell Bioscience Holdings Limited's operating cash flow?
Regencell Bioscience Holdings Limited (RGC) recorded an outflow of $3.1M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Regencell Bioscience Holdings Limited's total assets?
Regencell Bioscience Holdings Limited (RGC) had $5.8M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Regencell Bioscience Holdings Limited's capital expenditures?
Regencell Bioscience Holdings Limited (RGC) invested $153K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Regencell Bioscience Holdings Limited spend on research and development?
Regencell Bioscience Holdings Limited (RGC) invested $948K in research and development during fiscal year 2025.
What is Regencell Bioscience Holdings Limited's current ratio?
Regencell Bioscience Holdings Limited (RGC) had a current ratio of 7.39 as of fiscal year 2025, which is generally considered healthy.
What is Regencell Bioscience Holdings Limited's debt-to-equity ratio?
Regencell Bioscience Holdings Limited (RGC) had a debt-to-equity ratio of 0.18 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Regencell Bioscience Holdings Limited's return on assets (ROA)?
Regencell Bioscience Holdings Limited (RGC) had a return on assets of -62.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Regencell Bioscience Holdings Limited's P/E ratio?
Regencell Bioscience Holdings Limited (RGC) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $3.6B as of Oct 6, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Regencell Bioscience Holdings Limited's price-to-sales ratio?
Regencell Bioscience Holdings Limited (RGC) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $3.6B as of Oct 6, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Regencell Bioscience Holdings Limited's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Regencell Bioscience Holdings Limited (RGC) held $4.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $3.1M over that year. Dividing the one by the other, the reported balance equals about 19 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Regencell Bioscience Holdings Limited's Piotroski F-Score?
Regencell Bioscience Holdings Limited (RGC) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Regencell Bioscience Holdings Limited's earnings high quality?
Regencell Bioscience Holdings Limited (RGC) reported a net loss of $3.6M while operations used $3.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.